Attacking malignant cells that survive therapy: Exploiting immunogenic modulation

por Hodge, James W, Kwilas, Anna, Ardiani, Andressa, Gameiro, Sofia R
Publicado 2013

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens

por Gameiro, Sofia R, Ardiani, Andressa, Kwilas, Anna, Hodge, James W
Publicado 2014

Sublethal exposure to alpha radiation ((223)Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediat...

por Malamas, Anthony S., Gameiro, Sofia R., Knudson, Karin M., Hodge, James W.
Publicado 2016

Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies

por Lui, Grace, Minnar, Christine M., Soon-Shiong, Patrick, Schlom, Jeffrey, Gameiro, Sofia R.
Publicado 2023

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

por Gameiro, Sofia R., Malamas, Anthony S., Tsang, Kwong Y., Ferrone, Soldano, Hodge, James W.
Publicado 2016

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

por Knudson, Karin M., Hicks, Kristin C., Alter, Sarah, Schlom, Jeffrey, Gameiro, Sofia R.
Publicado 2019

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist

por Knudson, Karin M, Hicks, Kristin C, Ozawa, Yohei, Schlom, Jeffrey, Gameiro, Sofia R
Publicado 2020

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway

por Ardiani, Andressa, Gameiro, Sofia R., Kwilas, Anna R., Donahue, Renee N., Hodge, James W.
Publicado 2014

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin

por Kwilas, Anna R., Ardiani, Andressa, Gameiro, Sofia R., Richards, Jacob, Hall, Ashley B., Hodge, James W.
Publicado 2016

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

por Knudson, Karin M., Hicks, Kristin C., Luo, Xiaoling, Chen, Jin-Qiu, Schlom, Jeffrey, Gameiro, Sofia R.
Publicado 2018

Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa

por Ozawa, Yohei, Hicks, Kristin C., Minnar, Christine M., Knudson, Karin M., Schlom, Jeffrey, Gameiro, Sofia R.
Publicado 2021

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

por Gameiro, Sofia R., Jammed, Momodou L., Wattenberg, Max M., Tsang, Kwong Y., Ferrone, Soldano, Hodge, James W.
Publicado 2013

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

por Lind, Hanne, Gameiro, Sofia R, Jochems, Caroline, Donahue, Renee N., Strauss, Julius, Gulley, James L, Palena, Claudia, Schlom, Jeffrey
Publicado 2020

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

por Minnar, Christine M, Chariou, Paul L, Horn, Lucas A, Hicks, Kristin C, Palena, Claudia, Schlom, Jeffrey, Gameiro, Sofia R
Publicado 2022

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

por Friedman, Jay, Morisada, Megan, Sun, Lillian, Moore, Ellen C., Padget, Michelle, Hodge, James W., Schlom, Jeffrey, Gameiro, Sofia R., Allen, Clint T.
Publicado 2018

Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression

por Gameiro, Sofia R., Higgins, Jack P., Dreher, Matthew R., Woods, David L., Reddy, Goutham, Wood, Bradford J., Guha, Chandan, Hodge, James W.
Publicado 2013

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition...

por Fenerty, Kathleen E., Padget, Michelle, Wolfson, Benjamin, Gameiro, Sofia R., Su, Zhen, Lee, John H., Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Hodge, James W.
Publicado 2018

Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PA...

por Fenerty, Kathleen E., Padget, Michelle, Wolfson, Benjamin, Gameiro, Sofia R., Su, Zhen, Lee, John H., Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Hodge, James W.
Publicado 2019

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

por Hicks, Kristin C., Chariou, Paul L., Ozawa, Yohei, Minnar, Christine M., Knudson, Karin M., Meyer, Thomas J., Bian, Jing, Cam, Margaret, Schlom, Jeffrey, Gameiro, Sofia R.
Publicado 2021

Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity

por Hong, Youji, Robbins, Yvette, Yang, Xinping, Mydlarz, Wojciech K., Sowers, Anastasia, Mitchell, James B., Gulley, James L., Schlom, Jeffrey, Gameiro, Sofia R., Sievers, Cem, Allen, Clint T.
Publicado 2022